Recent clinical and molecular findings in low-grade serous ovarian carcinoma including prospects for personalized medicine using cancer organoids
Academia Oncology · 2025
DOI: 10.20935/acadonco7482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Academia Oncology, 2025. Verfasst von Kentaro Nakayama und 3 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
Low-grade serous ovarian carcinoma (LGSOC), classified as a type I ovarian cancer, develops from serous cystadenoma (SCA) through a serous borderline tumor (SBT). Reports on the oncogenesis of LGSOC have been primarily conducted in Western countries, with no reports from Japan. The authors have initiated comprehensive research on LGSOC, which was prompted by a case of LGSOC pathologically associated with SCA and SBT that are considered as precancerous lesions. In this case, the genetic mutations commonly reported in the West, including KRAS/BRAF abnormalities, were not observed. Therefore, the authors focused on the genetic analysis of Japanese LGSOC and SBT and found a high frequency of PIK3CA mutations, with a rare occurrence of KRAS/BRAF mutations. To elucidate the oncogenic mechanism of LGSOC, the authors established immortalized SCA cells and successfully constructed an in vitro LGSOC oncogenesis model by introducing oncogenes based on the aforementioned data. Furthermore, LGSOC with PIK3CA mutations were found to have a significantly higher frequency of estrogen receptor (ER) expression. As a result, the ER antagonist fulvestrant was shown to be effective. This review also introduces developments in personalized medicine using LGSOC organoids.
Zitieren
APA
Nakayama, K., Ishibashi, T., Ishikawa, M., & Kyo, S. (2025). Recent clinical and molecular findings in low-grade serous ovarian carcinoma including prospects for personalized medicine using cancer organoids. Academia Oncology. https://doi.org/10.20935/acadonco7482
Vancouver
Nakayama K, Ishibashi T, Ishikawa M, Kyo S. Recent clinical and molecular findings in low-grade serous ovarian carcinoma including prospects for personalized medicine using cancer organoids. Academia Oncology. 2025. doi:10.20935/acadonco7482
BibTeX
@article{Nakayama2025,
author = {Nakayama, Kentaro and Ishibashi, Tomoka and Ishikawa, Masako and Kyo, Satoru},
title = {Recent clinical and molecular findings in low-grade serous ovarian carcinoma including prospects for personalized medicine using cancer organoids},
journal = {Academia Oncology},
year = {2025},
doi = {10.20935/acadonco7482}
}
EUVIMED